Cited by

• Long noncoding RNA LINC00657 enhances the malignancy of pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on microRNA-433 to increase PAK4 expression.

  Bi S, Wang Y, Feng H, Li Q. Bi S, et al. Cell Cycle. 2020 Apr;19(7):801-816. doi: 10.1080/15384101.2020.1731645. Epub 2020 Mar 1. Cell Cycle. 2020. Retraction in: Cell Cycle. 2021 Dec;20(24):2664. doi: 10.1080/15384101.2021.1971876. PMID: 32116086 Free PMC article. Retracted.
• The significance of PAK4 in signaling and clinicopathology: A review.

  Yu X, Huang C, Liu J, Shi X, Li X. Yu X, et al. Open Life Sci. 2022 Jun 20;17(1):586-598. doi: 10.1515/biol-2022-0064. eCollection 2022. Open Life Sci. 2022. PMID: 35800076 Free PMC article. Review.
• Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

  Chandrashekar DS, Chakravarthi BVSK, Robinson AD, Anderson JC, Agarwal S, Balasubramanya SAH, Eich ML, Bajpai AK, Davuluri S, Guru MS, Guru AS, Naik G, Della Manna DL, Acharya KK, Carskadon S, Manne U, Crossman DK, Ferguson JE, Grizzle WE, Palanisamy N, Willey CD, Crowley MR, Netto GJ, Yang ES, Varambally S, Sonpavde G. Chandrashekar DS, et al. Oncogene. 2020 May;39(20):4077-4091. doi: 10.1038/s41388-020-1275-7. Epub 2020 Mar 30. Oncogene. 2020. PMID: 32231273
• Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents.

  Li Y, Lu Q, Xie C, Yu Y, Zhang A. Li Y, et al. Front Pharmacol. 2022 Aug 29;13:956220. doi: 10.3389/fphar.2022.956220. eCollection 2022. Front Pharmacol. 2022. PMID: 36105226 Free PMC article. Review.
• hsa-miR-199a-3p Inhibits Motility, Invasiveness, and Contractility of Ovarian Endometriotic Stromal Cells.

  Zhu R, Nasu K, Hijiya N, Yoshihashi M, Hirakawa T, Aoyagi Y, Narahara H. Zhu R, et al. Reprod Sci. 2021 Dec;28(12):3498-3507. doi: 10.1007/s43032-021-00604-4. Epub 2021 May 13. Reprod Sci. 2021. PMID: 33987822